Immix Biopharma, Inc (NASDAQ:IMMX)
Los Angeles, CA / Hybrid
Our 3 Core Values
What You'll Do
Skills and Experience We Look For
Rewards at Immix
Our people are our greatest asset, and supporting their well-being is an essential part of delivering on our mission and impacting the lives of patients. Putting this belief into practice means offering strong compensation and benefits. Compensation will be commensurate with experience. Our compensation package also includes an annual bonus based on company goals and an equity grant. Our benefits package includes: coverage for medical, dental and vision for team members and dependents and 401k.
About Immix Biopharma
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201, currently being evaluated in the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial. NXC-201 has the potential to be the world s first Single-Day CRS CAR-T, enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in multiple myeloma and AL Amyloidosis. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Immix Biopharma (Nasdaq: IMMX)
05/27/2024
Los Angeles,CA